Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry

Artif Organs. 2021 Jun;45(6):E187-E194. doi: 10.1111/aor.13900. Epub 2021 Feb 17.

Abstract

The coronavirus disease 2019 (COVID-19) has been shown to involve the gastrointestinal tract, which implies bacterial translocation and endotoxemia. The aim of this study was to evaluate the role of extracorporeal endotoxin removal by Polymyxin B hemoperfusion (PMX-HP), in the treatment of patients with COVID-19 and secondary bacterial infection. We conducted a subgroup analysis of a multicenter, multinational, prospective, and observational web-based database (EUPHAS2 registry). We included 12 patients with severe acute respiratory syndrome coronavirus 2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction from nasal/oral swab, admitted to the intensive care unit between February and May 2020, who were affected by septic shock and received PMX-HP as per clinical indication of the attending physician. Septic shock was diagnosed in nine patients (75%), with a median time between symptoms onset and PMX-HP treatment of 16 (14-22) days. We identified Gram-negative bacteria in most of the microbiological cultures (N = 17, 65%), followed by Gram-positive bacteria in (N = 4, 15%), fungi (N = 3, 12%) and no growth (N = 2, 8%). Sequential Organ Failure Assessment (SOFA) score progressively improved over the next 120 hours following PMX-HP and it was associated with median endotoxin activity assay (EAA) decrease from 0.78 [0.70-0.92] at T0 to 0.60 [0.44-0.72] at T120 (P = .245). A direct correlation was observed between SOFA score and EAA. Lung Injury Score decreased and was associated with hemodynamic improvement over the same period. No statistically significant difference was observed for RIFLE score at each time point. Nine out of 12 patients (75%) required continuous renal replacement therapy because of acute kidney injury. In a series of consecutive COVID-19 patients with endotoxic shock, PMX-HP was associated with organ function recovery, hemodynamic improvement, and contemporary EAA level reduction. No PMX-HP-related complications were observed.

Keywords: coronavirus disease 2019; endotoxic shock; hemoperfusion; polymyxin B.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Biomarkers / blood
  • COVID-19 / complications*
  • COVID-19 / mortality
  • Critical Illness
  • Endotoxemia / drug therapy*
  • Endotoxemia / microbiology*
  • Endotoxemia / mortality
  • Female
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Organ Dysfunction Scores
  • Polymyxin B / therapeutic use*
  • Prospective Studies
  • Registries
  • SARS-CoV-2
  • Shock, Septic / drug therapy*
  • Shock, Septic / microbiology*
  • Shock, Septic / mortality

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Polymyxin B